RxDoctor Payments Data

Caroline Imiolek, PA

Medical · Anchorage, AKNPI 1740988104

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,377 of the $2,044 with a category attached, or 67.3%. Medtronic accounts for 86.1% of it on its own, with 9 other manufacturers making up the rest.

$2,044in general payments, 2019–2025

Across 36 payments — averaging $56.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • AbbVie$83
  • Collegium Pharmaceutical, Inc.$42
  • Pfizer$41
  • Merz Pharmaceuticals, LLC$26
  • Abbott$22
  • plus $70 from 4 others

What the payments were for

  • Travel & lodging$1,37767%
  • Food & beverage$62230%
  • Education$452%

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,044 in reported general payments places this provider in the 75th percentile of 140 medical providers in Alaska.

See all medical providers in Alaska

Medicare billing

Part B allowed, 2024
$88,174
Medicare patients
374
Services billed
2,012

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate17$8,574
OxycontinOxycodone Hcl11$5,269
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen99$4,208
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen110$3,025
Oxycodone Hcl103$2,126
Fentanyl21$1,784
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl11$1,474
Morphine Sulfate ErMorphine Sulfate68$1,427
Lidocaine16$1,108
Gabapentin90$797
Pregabalin43$571
Tizanidine Hcl88$546
Morphine Sulfate21$539
Tramadol Hcl28$240
Cyclobenzaprine Hcl31$198

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$42$8,57417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 140 medical providers in Alaska.

Other medical in Anchorage

See the full list for Alaska

Where these figures come from

Is this you, or does something look wrong? →